Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2019-10-10 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于第四届监事会第六次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at the sixth meeting of the fourth Supervisory Board of 特一药业集团股份有限公司. It details decisions regarding the use of idle raised funds for temporary liquidity and cash management. The document includes voting results and compliance statements but does not contain financial statements or detailed financial data. It is a formal announcement related to corporate governance and fund usage approvals, not a full report or financial statement. The document length is short (1333 characters), and it serves as a formal disclosure of meeting resolutions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2019-10-10 Chinese
国信证券股份有限公司关于公司使用部分闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from the sponsor (Guosen Securities Co., Ltd.) regarding the use of part of idle raised funds by Te Yi Pharmaceutical Group Co., Ltd. for cash management. It references regulatory rules related to securities issuance and listing, details the amount and use of raised funds, and provides the sponsor's audit and approval opinion on the company's cash management activities. The document does not contain financial statements or detailed financial results but is a formal verification and opinion letter related to the company's use of funds. It is not an annual or interim report, earnings release, or audit report. It is also not a simple announcement of a report publication. Given the nature of the document as a sponsor's verification opinion on a specific financial activity, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and verification documents that do not fit other specific categories.
2019-10-10 Chinese
关于第四届董事会第六次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board of directors meeting of 特一药业集团股份有限公司. It details the date and attendance of the meeting, the agenda items discussed, and the voting results on financial decisions related to the use of idle raised funds and cash management. There is no detailed financial data or comprehensive report content, but rather a formal disclosure of board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2019-10-10 Chinese
关于使用部分闲置募集资金进行现金管理到期赎回的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 特一药业集团股份有限公司 regarding the use of idle raised funds for cash management and the maturity redemption of related financial products. It details specific financial products, their amounts, terms, and actual returns. The document is a formal disclosure about the company's cash management activities and the results of these investments. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is not a call transcript, board change announcement, or legal proceeding update. The document is a specific update on financing activities related to the use of raised funds and cash management products. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 5578 characters, which is sufficient for a substantive announcement rather than a brief notice. Hence, the classification is CAP with high confidence.
2019-10-09 Chinese
2019年第三季度可转换公司债券转股情况公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the convertible bonds (可转换公司债券) of 特一药业集团股份有限公司 for the third quarter of 2019. It details the bond issuance, conversion price adjustments, and the changes in shareholding due to bond conversions during the quarter ending September 30, 2019. The document includes specific data on bond conversion amounts and share changes but does not contain comprehensive financial statements or a full quarterly report. It is a regulatory announcement about bond conversion and shareholding changes rather than a full interim or quarterly financial report. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as convertible bond conversions.
2019-10-08 Chinese
简式权益变动报告书（一）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the changes in shareholding of certain individuals and entities in 特一药业集团股份有限公司, including the number of shares before and after the transaction, the nature of the share transfer (agreement transfer), and related legal and regulatory compliance statements. It includes detailed information about the shareholders, the transfer agreement, and the impact on control and shareholding percentages. There is no financial performance data, earnings information, or management discussion of financial results. The document is a formal disclosure of changes in major shareholdings and related agreements, consistent with notifications of significant share ownership changes. Therefore, the document fits the category of Major Shareholding Notification (MRQ). The document length and detail confirm it is the report itself, not just an announcement or certification.
2019-09-23 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.